Dr Nadia Mazarakis
Dr Nadia Mazarakis
Details
Role
Senior Research Officer
Research area
Infection, Immunity and Global Health
Group
Vaccine Immunology
Dr Nadia Mazarakis is a senior research officer in the Vaccine Immunology group under A/Prof Paul Licciardi at Murdoch Children’s Research Institute (MCRI). Her current research focuses on evaluating the immunogenicity of COVID-19 vaccines as a booster dose in a global randomised controlled trial. Nadia also has an honorary appointment with the University of Melbourne, Faculty of Medicine, Dentistry and Health Sciences, Department of Paediatrics.
She completed her PhD at the University of Melbourne in 2021. Her PhD thesis evaluated the critical biological health-benefiting properties of the dietary compound L-sulforaphane (LSF) in relevant models of inflammatory disease. Prior to her PhD, she completed a Masters of Bioethics at Monash University.
She completed her PhD at the University of Melbourne in 2021. Her PhD thesis evaluated the critical biological health-benefiting properties of the dietary compound L-sulforaphane (LSF) in relevant models of inflammatory disease. Prior to her PhD, she completed a Masters of Bioethics at Monash University.
Dr Nadia Mazarakis is a senior research officer in the Vaccine Immunology group under A/Prof Paul Licciardi at Murdoch Children’s Research Institute (MCRI). Her current research focuses on evaluating the immunogenicity of COVID-19 vaccines as a...
Dr Nadia Mazarakis is a senior research officer in the Vaccine Immunology group under A/Prof Paul Licciardi at Murdoch Children’s Research Institute (MCRI). Her current research focuses on evaluating the immunogenicity of COVID-19 vaccines as a booster dose in a global randomised controlled trial. Nadia also has an honorary appointment with the University of Melbourne, Faculty of Medicine, Dentistry and Health Sciences, Department of Paediatrics.
She completed her PhD at the University of Melbourne in 2021. Her PhD thesis evaluated the critical biological health-benefiting properties of the dietary compound L-sulforaphane (LSF) in relevant models of inflammatory disease. Prior to her PhD, she completed a Masters of Bioethics at Monash University.
She completed her PhD at the University of Melbourne in 2021. Her PhD thesis evaluated the critical biological health-benefiting properties of the dietary compound L-sulforaphane (LSF) in relevant models of inflammatory disease. Prior to her PhD, she completed a Masters of Bioethics at Monash University.
Top Publications
- Mazarakis, N, Toh, ZQ, Neal, E, Nguyen, C, Bright, K, Luu, S, Quah, L, Ng, YY, Hart, J, Do, LAH, et al. Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia.. J Infect 106727 2026 view publication
- Toh, ZQ, Anderson, J, Mazarakis, N, Neeland, M, Higgins, RA, Rautenbacher, K, Dohle, K, Nguyen, J, Overmars, I, Donato, C, et al. Reduced seroconversion in children compared to adults with mild COVID-19. 2026 view publication
- Royce, S, Licciardi, P, Beh, R, Bourke, J, Cooper, M, Donovan, C, Hung, A, Khurana, I, Liang, J, Maxwell, S, et al. Sulforaphane prevents and reverses allergic airways disease in mice via anti-inflammatory, antioxidant and epigenetic mechanisms. 2026 view publication
- Toh, ZQ, Mazarakis, N, Nguyen, J, Higgins, RA, Anderson, J, Ha, LA, Burgner, DP, Curtis, N, Steer, AC, Mulholland, K, et al. Comparison of antibody responses to SARS-CoV-2 variants in Australian children. 2026 view publication
- Mazarakis, N, Toh, ZQ, Nguyen, J, Higgins, RA, Rudge, J, Whittle, B, Woudberg, NJ, Devine, J, Gooley, A, Lapierre, F, et al. Evaluation of SARS-CoV-2 antibody response between paired fingerprick (hemaPEN®) and venepuncture collected samples in children and adults. 2026 view publication
Page 1 of 7
Career information
Share //
